Abstract
The molecular chaperone, heat shock protein 70 (Hsp70), acts at multiple steps in a proteins life cycle, including during the processes of folding, trafficking, remodeling and degradation. To accomplish these various tasks, the activity of Hsp70 is shaped by a host of co-chaperones, which bind to the core chaperone and influence its functions. Genetic studies have strongly linked Hsp70 and its co-chaperones to numerous diseases, including cancer, neurodegeneration and microbial pathogenesis, yet the potential of this chaperone as a therapeutic target remains largely underexplored. Here, we review the current state of Hsp70 as a drug target, with a special emphasis on the important challenges and opportunities imposed by its co-chaperones, protein-protein interactions and allostery.
Keywords: Proteostasis, flavonoids, dihydropyrimidines, spergualin, sulfoglycolipids, geranylgeranyl acetone, protein folding, ATPase, protein-protein interactions
Current Topics in Medicinal Chemistry
Title: Pharmacological Targeting of the Hsp70 Chaperone
Volume: 9 Issue: 15
Author(s): Srikanth Patury, Yoshinari Miyata and Jason E. Gestwicki
Affiliation:
Keywords: Proteostasis, flavonoids, dihydropyrimidines, spergualin, sulfoglycolipids, geranylgeranyl acetone, protein folding, ATPase, protein-protein interactions
Abstract: The molecular chaperone, heat shock protein 70 (Hsp70), acts at multiple steps in a proteins life cycle, including during the processes of folding, trafficking, remodeling and degradation. To accomplish these various tasks, the activity of Hsp70 is shaped by a host of co-chaperones, which bind to the core chaperone and influence its functions. Genetic studies have strongly linked Hsp70 and its co-chaperones to numerous diseases, including cancer, neurodegeneration and microbial pathogenesis, yet the potential of this chaperone as a therapeutic target remains largely underexplored. Here, we review the current state of Hsp70 as a drug target, with a special emphasis on the important challenges and opportunities imposed by its co-chaperones, protein-protein interactions and allostery.
Export Options
About this article
Cite this article as:
Patury Srikanth, Miyata Yoshinari and Gestwicki E. Jason, Pharmacological Targeting of the Hsp70 Chaperone, Current Topics in Medicinal Chemistry 2009; 9 (15) . https://dx.doi.org/10.2174/156802609789895674
DOI https://dx.doi.org/10.2174/156802609789895674 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
From Protein to Peptides: a Spectrum of Non-Hydrolytic Functions of Acetylcholinesterase
Protein & Peptide Letters Metabotropic Glutamate Receptor Ligands as Potential Therapeutics for Addiction
Current Drug Abuse Reviews Spin Trapping: An Essential Tool for the Study of Diseases Caused by Oxidative Stress
Current Topics in Medicinal Chemistry Potential Therapeutic Application of Chondroitin Sulfate/Dermatan Sulfate
Current Drug Discovery Technologies Melatonin Regulates Angiogenic Factors under Hypoxia in Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry From Na+/K+-ATPase and Cardiac Glycosides to Cytotoxicity and Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry LRIGs: A Prognostically Significant Family with Emerging Therapeutic Competence against Cancers
Current Cancer Drug Targets Endothelial Progenitor Cells: Hope Beyond Controversy
Current Cancer Drug Targets Synthesis and SARs of Coumarin Fused 1,5-Benzothiazepines as Novel Anticancer and Antioxidant Agents
Mini-Reviews in Organic Chemistry Design of New Improved Curcumin Derivatives to Multi-targets of Cancer and Inflammation
Current Drug Targets Chemoradiotherapy of Human Tumors: Novel Approaches from Nanomedicine
Current Pharmaceutical Design Namitecan: a Hydrophilic Camptothecin with a Promising Preclinical Profile
Current Medicinal Chemistry Radiopharmaceuticals for Oncology Drug Development: A Pharmaceutical Industry Perspective
Current Pharmaceutical Design Regulation of Epithelial-Mesenchymal Transition by E3 Ubiquitin Ligases and Deubiquitinase in Cancer
Current Cancer Drug Targets Adding to the Mix: Fibroblast Growth Factor and Platelet-Derived Growth Factor Receptor Pathways as Targets in Non – small Cell Lung Cancer
Current Cancer Drug Targets The Antimitotic Potential of PARP Inhibitors, An Unexplored Therapeutic Alternative
Current Topics in Medicinal Chemistry The Complex Biology of FOXO
Current Drug Targets TRAIL Agonists on Clinical Trials for Cancer Therapy: The Promises and the Challenges
Reviews on Recent Clinical Trials Current Developments in Targeted Drug Delivery Systems for Glioma
Current Pharmaceutical Design Neuropeptide-Derived Antimicrobial Peptides from Invertebrates for Biomedical Applications
Current Medicinal Chemistry